Search

Background Many patients with American College of Cardiology/American Heart Association Stage D (advanced) heart failure are discharged home on chronic intravenous inotropic support (CIIS) as bridge to surgical therapy or as palliative therapy. This study analyzed the clinical trajectory of patients with advanced heart failure who were on home CIIS. Methods We conducted a single-institution, retrospective cohort study of patients on CIIS between 2010 and 2016 (n = 373), stratified by indication for initiation of inotropic support. Study outcomes were time from initiation of CIIS to cessation of therapy, time to death for patients who did not receive surgical therapy and rates of involvement with palliative care. Results Overall, patients received CIIS therapy for an average of 5.9 months (standard deviation [SD] 7.3). Patients on CIIS as palliative therapy died in an average of 6.2 months (SD 6.6) from the time of initiation of CIIS, and those on CIIS as bridge therapy who did not ultimately receive surgical therapy died after an average of 8.6 months (SD 9.3). Patients who received CIIS as bridge therapy were significantly less likely to receive palliative-care consultation than those on inotropes as palliative therapy, whether or not they underwent surgery. Conclusions In this large cohort of patients with advanced HF, patients who on CIIS as palliative therapy survived for 6.2 months, on average, with wide variation among patients. Patients who were on CIIS as bridge therapy but did not ultimately receive surgical therapy received less palliative care despite the high mortality rate in this subgroup.

Background Women differ from men in their left ventricular (LV) structure, function and remodeling with age and diseases. The LV assist device (LVAD) unloads the LV and reversely remodels the heart. We sought to define the effects of sex on longitudinal reverse remodeling after LVAD implantation. Methods and Results Cardiac structure and function were assessed by serial echocardiograms. Mixed effect regression models were constructed to assess the independent contribution of sex to longitudinal changes in cardiac structure and function. A total of 355 consecutive patients with advanced heart failure received continuous flow LVADs between 2006 and 2016. The average age was 56 ± 13 years, 73% were men, and 67% were black. Early (within 3 months) after LVAD implantation, women had a greater reduction in LV dimensions and a greater increase in LV ejection fraction compared with men. These differences were independent of age, body surface area, device type, or ischemic etiology of heart failure. At long-term follow-up, LV dimensions increased slightly over time in women compared with men, but overall, earlier changes were maintained. Conclusion Women had significantly more favorable longitudinal changes in cardiac structure and function in response to LV unloading compared with men. Understanding the cause of sex difference in reverse remodeling after LVAD may help to devise novel therapeutic strategies for women with advanced heart failure.

Durable mechanical circulatory support (MCS) therapy improves survival in patients with advanced heart failure. Knowledge regarding the outcomes experienced by patients with inflammatory cardiomyopathy (CM) who receive durable MCS therapy is limited.We compared patients with inflammatory CM with patients with idiopathic dilated CM enrolled in the STS-INTERMACS registry. Among 19,012 patients, 329 (1.7%) had inflammatory CM and 5978 had idiopathic dilated CM (31.4%). The patients with inflammatory CM were younger, more likely to be White, and women. These patients experienced more preoperative arrhythmias and higher use of temporary MCS. Patients with inflammatory CM had a higher rate of early adverse events (3 months after device implant), including bleeding, arrhythmias, non-device-related infections, neurologic dysfunction, and respiratory failure. The rate of late adverse events (≥3 months) was similar in the 2 groups. Patients with inflammatory CM had a similar 1-year (80% vs 84%) and 2-year (72% vs 76%, P = .15) survival. Myocardial recovery resulting in device explant was more common among patients with inflammatory CM (5.5% vs 2.3%, P.001).Patients with inflammatory CM who received durable MCS appear to have a similar survival compared with patients with idiopathic dilated CM despite a higher early adverse event burden. Our findings support the use of durable MCS in an inflammatory CM population.

Background: Optimization of health care delivery in different settings with the goal of improving quality of life and reduction of heart failure (HF) morbidity continues to be an unmet need. Digital engagement between patients and providers is becoming more prevalent for care coordination and management of heart failure.Aims: To design and test a customized and interactive heart failure disease specific functionality with activated technology (Amazon's Echo Dot or an Avatar) as a tool for management of HF patients at home. To identify the effect of a voice activated technology in the reduction of heart failure hospitalizations, improvement of medication adherence, improvement in health-related quality of life and increase in comfort with voice activated technologies. Methods We compared two types of conversational agent technologies to standard of care, using speech recognition, to evaluate patient engagement in HF patients. The first technologyutilized the Amazon Echo Dot Alexa technology and only communicated with the patient through audio and the second was an application on a tablet using an Avatar, combining audio and visual. The conversational agent asks the HF patients a series of 11 questions, divided into three components: compliance (questions 1-3), mild HF symptoms (questions 4-6) and moderate/severe HF symptoms (questions 7-11). Participants completed questions regarding their use and comfort with technology. Inclusion criteria: admitted or treated for HF;18 or older; and resides with access to wifi. Exclusion criteria: heart transplant or ventricular assist device recipients. Participants were monitored for three months.Results: Thirty patients were enrolled in each intervention arm of the two studies with the Alexa or Avatar. Mean age was 54 years in the Alexa group and 56 years in the Avatar group. There were predominately males 61% and 63%, Alexa and Avatar, respectively. In the Alexa and Avatar groups race was predominately black, 64% and 63% followed by white 21% and 30%. The Alexa group was statistically more likely to complete the three compliance factors of weight checking (p=.030), salt monitoring (p=0.016) and medication adherence (p=0.005). Initial results suggest that older people and individuals using the smart phone answer the questionnaire at higher rates, and individuals taking an increased number of medications to treat HF had lower participation.Conclusion: Voice enabled, internet connected devices are poised to have profound impacts on the quality of life for in-home, independent, and assisted-living patients by vastly increasing the connectivity to healthcare providers.

Background There is limited published literature on acute eosinophilic myocarditis (EM), a rare form of acute myocarditis, wherein eosinophils invade the myocardium with wide-ranging clinical sequalae. We aim to describe our experience in the largest contemporary case series of histologically-proven EM. Methods Two authors independently reviewed the surgical pathology and autopsy databases for acute EM (01/2009 to 12/2017). Only patients with endomyocardial biopsy/autopsy and clinical course consistent with acute EM were included. We abstracted demographic data, comorbidities, clinical diagnostics, and clinical outcomes. Results Seven patients had acute EM (Table). The average age was 53-years and five subjects were women. The most common etiology of EM was idiopathic. Five patients had peripheral eosinophilia. Three patients had elevated pulmonary capillary wedge pressure and three patients had reduced cardiac output. Six patients were treated with steroids, four of whom received IV pulse dosed steroids. Two patients required intra-aortic balloon pump support, one of whom subsequently underwent durable left ventricular assist device implantation. Two patients died during index hospitalization, one of septic shock and one of refractory ventricular tachycardia. Conclusion The etiologies, clinical presentation, and course of acute EM varied widely. Prompt diagnosis, treatment with immunosuppression, and circulatory support may reduce cardiovascular mortality in this population.

Background: Mammalian target of rapamycin (mTOR) is a kinase which modulates cell growth by enhancing protein synthesis (in part via phosphorylation of ribosomal S6 protein (RS6P)) and inhibiting autophagy. Advanced heart failure (HF) activates enzymes in pathways both down stream and independent of mTOR. While short term mTOR inhibition with rapamycin ameliorates LV hypertrophy (LVH), the effect of chronic rapamycin in advanced established HF and the role of reduced protein synthesis vs. increased autophagy are unclear. We hypothesized that rapamycin ameliorates LVH and systolic dysfunction associated with inhibition of protein synthesis (decreased phosphorylation of RS6P) and increased autophagy (increased microtubule-associated protein light chain 3-II (LC3-II), marker of autophagosome formation). Methods: 8 week old C57/BL6 mice underwent transverse aortic constriction (TAC). 3 weeks after TAC, mice underwent echo and those with severe systolic dysfunction were randomized to placebo or rapamycin 8 mg/kg/day orally for 6 weeks followed by echo, hemodynamics and LV harvest for western blots. Age/sex matched non-banded mice were controls. Results: Trough blood rapamycin level was 13.3 6 7.5 ng/ml in HF + rapamycin mice. Compared to HF, HF + rapamycin mice had higher ejection fraction (EF), less hypertrophy and milder HF (lower lung:body weight). Systolic LV pressures were higher in HF + rapamycin reflecting severe TAC but better systolic function. RS6P phosphorylation was lower in HF but not further reduced in HF + rapamycin. LC3-II expression was higher in HF + rapamycin.